
Antonio Di Stasi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6169432/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	IDH1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemia. Cancer Treatment and Research Communications, 2022, 31, 100560.	1.7	2
2	Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia. Leukemia Research, 2022, 117, 106844.	0.8	7
3	Passenger Lymphocyte Syndrome and Autoimmune Hypothyroidism Following Hematopoietic Stem Cell Transplantation. Case Reports in Immunology, 2022, 2022, 1-6.	0.4	1
4	Survival outcomes of patients with relapsed or refractory acute myeloid leukemia after venetoclax combined with hypomethylating agents Journal of Clinical Oncology, 2022, 40, e18808-e18808.	1.6	0
5	Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantation. Bone Marrow Transplantation, 2021, 56, 1364-1372.	2.4	4
6	Phase <scp>II</scp> clinical trial of one dose of postâ€transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matchedâ€unrelated donor transplantation. American Journal of Hematology, 2021, 96, E396-E398.	4.1	4
7	Observation Versus Immediate Reinduction for Acute Myeloid Leukemia Patients With Indeterminate Day 14 Bone Marrow Results. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 31-38.	0.4	3
8	Generation of Suicide Gene-Modified Chimeric Antigen Receptor-Redirected T-Cells for Cancer Immunotherapy. Methods in Molecular Biology, 2019, 1895, 57-73.	0.9	29
9	Clinical-scale manufacturing of γδT cells for protection against infection and disease recurrence following haploidentical peripheral blood stem cell transplantation and cyclophosphamide gvhd prophylaxis. Bone Marrow Transplantation, 2018, 53, 766-769.	2.4	8
10	Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant. Bone Marrow Transplantation, 2018, 53, 1345-1348.	2.4	4
11	Exploiting Cell Death Pathways for Inducible Cell Elimination to Modulate Graft-versus-Host-Disease. Biomedicines, 2017, 5, 30.	3.2	5
12	In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. PLoS ONE, 2016, 11, e0166891.	2.5	72
13	Seatbelts in CAR therapy: How Safe Are CARS?. Pharmaceuticals, 2015, 8, 230-249.	3.8	42
14	Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies. Frontiers in Immunology, 2015, 6, 36.	4.8	88
15	Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood, 2015, 125, 4103-4113.	1.4	188
16	Regulated Apoptosis of Genetically Modified Hematopoietic Stem and Progenitor Cells Via an Inducible Caspase-9 Suicide Gene in Rhesus Macaques. Stem Cells, 2015, 33, 91-100.	3.2	28
17	Improving the safety of cell therapy products by suicide gene transfer. Frontiers in Pharmacology, 2014, 5, 254.	3.5	165
18	Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood, 2014, 123, 3895-3905.	1.4	161

ANTONIO DI STASI

#	Article	IF	CITATIONS
19	Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy. New England Journal of Medicine, 2011, 365, 1673-1683.	27.0	1,264
20	Gene Therapy to Improve Migration of T Cells to the Tumor Site. Methods in Molecular Biology, 2010, 651, 103-118.	0.9	9
21	T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood, 2009, 113, 6392-6402.	1.4	458
22	Epstein Barr virus–specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood, 2007, 110, 2620-2630.	1.4	227